Rare chromosome abnormalities, prevalence and prenatal diagnosis rates from population-based congenital anomaly registers in Europe, European Journal of Human Genetics, vol.42, issue.5, pp.521-527, 2012. ,
DOI : 10.1136/adc.2003.026880
Presence of fetal DNA in maternal plasma and serum. Lancet, Aug, vol.16350, issue.9076, pp.485-492, 1997. ,
Le Diagnostic Prénatal Non Invasif (DPNI) : actualité sur les tests prénataux de dépistage et de diagnostic, 2013. ,
Maternal age- and gestation-specific risk for trisomy 21, Ultrasound in Obstetrics and Gynecology, vol.13, issue.3, 1999. ,
DOI : 10.1046/j.1469-0705.1999.13030167.x
Non-invasive prenatal testing for fetal chromosomal abnormalities by low-coverage whole-genome sequencing of maternal plasma DNA: review of 1982 consecutive cases in a single center, Ultrasound in Obstetrics & Gynecology, vol.41, issue.3, pp.254-64, 2014. ,
DOI : 10.1002/uog.13277
Gestational age and maternal weight effects on fetal cell-free DNA in maternal plasma, Prenatal Diagnosis, vol.29, issue.8, 2013. ,
DOI : 10.1002/pd.4119
Review: Cell-free fetal DNA in the maternal circulation as an indication of placental health and disease, Placenta, vol.35, p.2014 ,
DOI : 10.1016/j.placenta.2013.11.014
Free fetal DNA in maternal plasma in anembryonic pregnancies: confirmation that the origin is the trophoblast, Prenatal Diagnosis, vol.184, issue.5, pp.415-423, 2007. ,
DOI : 10.1002/pd.1700
DNA Sequencing versus Standard Prenatal Aneuploidy Screening, New England Journal of Medicine, vol.370, issue.9, pp.799-808, 2014. ,
DOI : 10.1056/NEJMoa1311037
Implementation of maternal blood cell-free DNA testing in early screening for aneuploidies, Ultrasound in Obstetrics & Gynecology, vol.31, issue.374, pp.34-40 ,
DOI : 10.1002/uog.12504
Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study, BMJ, vol.342, issue.jan11 1, p.7401, 2011. ,
DOI : 10.1136/bmj.c7401
DNA Sequencing of Maternal Plasma to Detect Down Syndrome, Obstetrical & Gynecological Survey, vol.67, issue.2, pp.913-933, 2011. ,
DOI : 10.1097/OGX.0b013e318247c6bf
78 study. First trimester Down syndrome screening program using nuchal translucency and maternal serum markers: the Echo PAPP-A.78 study, J Gynecol Obstet Biol Reprod, 2004. ,
Noninvasive prenatal aneuploidy testing of chromosomes 13, 18, 21, X, and Y, using targeted sequencing of polymorphic loci, Prenatal Diagnosis, vol.206, issue.1, Supplement, pp.1233-1274, 2012. ,
DOI : 10.1002/pd.3993
Analysis of the Size Distributions of Fetal and Maternal Cell-Free DNA by Paired-End Sequencing, Clinical Chemistry, vol.56, issue.8 ,
DOI : 10.1373/clinchem.2010.144188
A Case of False Negative NIPT for Down Syndrome-Lessons Learned, Case Reports in Genetics, vol.2014, p.823504, 2014. ,
DOI : 10.1073/pnas.0810641105
Accepting or declining the offer of prenatal screening for congenital defects: test uptake and women's reasons. Prenat Diagn, pp.84-90, 2005. ,
Circulating Fetal DNA: Its Origin and Diagnostic Potential???A Review, Placenta, vol.25 ,
DOI : 10.1016/j.placenta.2004.01.005
Revisiting the Fetal Loss Rate After Second-Trimester Genetic Amniocentesis, Obstetrics & Gynecology, vol.111, issue.3, pp.589-95, 2008. ,
DOI : 10.1097/AOG.0b013e318162eb53
Introducing the non-invasive prenatal test for trisomy 21 in Belgium: a cost-consequences analysis, BMJ Open, vol.4, issue.11, 2014. ,
DOI : 10.1136/bmjopen-2014-005922
A cost-effectiveness analysis comparing different strategies to implement noninvasive prenatal testing into a Down syndrome screening program, Australian and New Zealand Journal of Obstetrics and Gynaecology, vol.26, issue.5, pp.412-419, 2014. ,
DOI : 10.1111/ajo.12223
American Hospital of Paris et transmis pour analyse au laboratoire SEQUENOM CMM (Center for Molecular Medicine) USA, qui est le laboratoire spécialisé ayant aujourd'hui la plus grande expérience dans ce domaine ,
ADN libre circulant dans le sang maternel Ce test est indiqué chez les femmes enceintes présentant un risque accru de trisomie des chromosomes 21 ,